RS20050514A - Compounds having prolyl oligopeptidase inhibitory activity - Google Patents

Compounds having prolyl oligopeptidase inhibitory activity

Info

Publication number
RS20050514A
RS20050514A YUP-2005/0514A YUP20050514A RS20050514A RS 20050514 A RS20050514 A RS 20050514A YU P20050514 A YUP20050514 A YU P20050514A RS 20050514 A RS20050514 A RS 20050514A
Authority
RS
Serbia
Prior art keywords
compounds
prolyl oligopeptidase
inhibitory activity
formula
treatment
Prior art date
Application number
YUP-2005/0514A
Other languages
English (en)
Inventor
Jukka Gynther
Erik Wallen
Elina Jarho
Pekka Mannisto
Markus Forsberg
Antti Poso
Johannes Christiaans
Jarkko Venalainen
Jouko Vepsalainen
Taija Saarinen
Tomi Jarvinen
Original Assignee
Orion Corporation,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corporation, filed Critical Orion Corporation,
Publication of RS20050514A publication Critical patent/RS20050514A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Ovaj pronalazak obezbedjuje jedinjenje formule (I), gde su X, R1, R2 i R3 kao što su definisani zahtevom 1 ili njegovu farmaceutski prihvatljivu so ili estar, koji se koristi kao inhibitor prolil oligopeptidaze. Jedinjenja formule (I) se mogu koristiti u lečenju oboljenja ili stanja u kojima su inhibitori prolil oligopeptidaze indikovani kao efektivni, na primer, u lečenju neurodegenerativnih oboljenja kao što su Alchajmerova bolest ili senilna demencija.
YUP-2005/0514A 2003-01-03 2004-01-02 Compounds having prolyl oligopeptidase inhibitory activity RS20050514A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20030014A FI20030014A0 (fi) 2003-01-03 2003-01-03 Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä
PCT/FI2004/000001 WO2004060862A2 (en) 2003-01-03 2004-01-02 Compounds having prolyl oligopeptidase inhibitory activity

Publications (1)

Publication Number Publication Date
RS20050514A true RS20050514A (en) 2007-12-31

Family

ID=8565256

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0514A RS20050514A (en) 2003-01-03 2004-01-02 Compounds having prolyl oligopeptidase inhibitory activity

Country Status (18)

Country Link
US (1) US20060229254A1 (sr)
EP (1) EP1581489A2 (sr)
JP (1) JP2006516557A (sr)
KR (1) KR20060027789A (sr)
CN (1) CN1747930A (sr)
AU (1) AU2004203788A1 (sr)
BR (1) BRPI0406618A (sr)
CA (1) CA2511856A1 (sr)
EA (1) EA010022B1 (sr)
FI (1) FI20030014A0 (sr)
HR (1) HRP20050693A2 (sr)
IS (1) IS7963A (sr)
MX (1) MXPA05007262A (sr)
NO (1) NO20053726L (sr)
PL (1) PL378329A1 (sr)
RS (1) RS20050514A (sr)
WO (1) WO2004060862A2 (sr)
ZA (1) ZA200505183B (sr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56751B1 (sr) * 2009-12-18 2018-04-30 Ogeda Sa Derivati pirolidin karboksilne kiseline kao agonisti g-protein spojenog receptora 43 (gpr43), farmaceutska kompozicija i postupci za upotrebu u lečenju metaboličkih poremećaja
EP2730571A1 (en) 2012-11-12 2014-05-14 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
EP3610872A1 (en) 2013-11-27 2020-02-19 Epics Therapeutics Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
KR101913506B1 (ko) * 2017-07-18 2018-10-30 경상대학교산학협력단 프롤릴 올리고펩티다아제 억제제를 유효성분으로 함유하는 퇴행성 뇌질환 예방 또는 치료용 조성물
WO2022008477A1 (en) 2020-07-07 2022-01-13 Accure Therapeutics, S.L. 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483991A (en) * 1983-01-17 1984-11-20 American Home Products Corporation Hypotensive agents
EP0201741B1 (en) * 1985-04-16 1991-07-31 Suntory Limited Dipeptide derivatives, processes for preparing them, pharmaceutical composition and use
CA1320734C (en) * 1986-02-04 1993-07-27 Suntory Limited Pyrrolidineamide derivative of acylamino acid and pharmaceutical composition containing the same
JPH0696563B2 (ja) * 1986-02-04 1994-11-30 サントリー株式会社 アシルアミノ酸誘導体、その製法並びに用途
JP2511605B2 (ja) * 1990-06-04 1996-07-03 ファイザー・インコーポレーテッド 芳香性ピロリジンおよびチアゾリヂンアミド類
AU643300B2 (en) * 1990-06-07 1993-11-11 Zeria Pharmaceutical Co., Ltd. Novel arylalkanoylamine derivative and drug containing the same
EP0915088B1 (en) * 1997-10-31 2002-09-18 F. Hoffmann-La Roche Ag D-Proline derivatives

Also Published As

Publication number Publication date
ZA200505183B (en) 2006-04-26
EP1581489A2 (en) 2005-10-05
NO20053726L (no) 2005-09-28
US20060229254A1 (en) 2006-10-12
EA200501083A1 (ru) 2006-02-24
IS7963A (is) 2005-07-28
MXPA05007262A (es) 2005-09-08
CN1747930A (zh) 2006-03-15
HRP20050693A2 (en) 2005-10-31
JP2006516557A (ja) 2006-07-06
NO20053726D0 (no) 2005-08-03
FI20030014A0 (fi) 2003-01-03
KR20060027789A (ko) 2006-03-28
CA2511856A1 (en) 2004-07-22
WO2004060862A3 (en) 2004-11-25
WO2004060862A2 (en) 2004-07-22
PL378329A1 (pl) 2006-03-20
EA010022B1 (ru) 2008-06-30
BRPI0406618A (pt) 2005-12-06
AU2004203788A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
MY138797A (en) Bacterial gyrase inhibitors and uses thereof
WO2004022523A3 (en) 1, 3-diamino-2-hydroxypropane prodrug derivatives
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
CA2367017A1 (en) Inhibitors of impdh enzyme
GB0223040D0 (en) Therapeutic compounds
MXPA05011150A (es) 2-hidroxi-3-diaminoalcanos de benzamida.
WO2004087699A3 (en) Thiazoles useful as inhibitors of protein kinases
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004087698A3 (en) Thiazoles useful as inhibitors of protein kinases
PL1685142T3 (pl) Pochodne kwasu fosfinowego, inhibitory beta-sekterazy do leczenia choroby Alzheimera
MXPA04000328A (es) Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer.
ATE368031T1 (de) Neue gamma secretase inhibitoren
SG162790A1 (en) Aspartyl protease inhibitors
MXPA04002785A (es) Aminas sustituidas para tratamiento de enfermedad de alzheimer.
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
AU2005313582A8 (en) Malonamide derivatives as inhibitors of gamma-secretase for the treatment of Alzheimer's disease
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
TW200420545A (en) 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
RS87204A (en) Polycyclic compounds as potent alpha2-adrenoceptor antagonists
MXPA03011521A (es) Aminadioles para tratamiento de enfermedad de alzheimer.
NO20053726L (no) Forbindelser med prolyloligopeptidase-hemmende aktivitet
WO2008036316A3 (en) Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease